Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
A technology for urothelial carcinoma and PD-1, applied in drug combinations, antibodies, anti-tumor drugs, etc., can solve problems such as impaired immune response
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0234] Research design
[0235] Described below is the use of moxibustion in combination with pembrolizumab in subjects with locally advanced or metastatic transitional cell urothelial carcinoma (mUC) previously treated with 0-2 chemotherapy regimens in the metastatic setting. An open-label, single-arm, multicenter, phase 1b / 2 study of Librelin. Figure 8 An example of the study design of a phase 1b / 2, open-label, single-arm, multicentre trial is shown. The number of subjects provided below for each phase of the study is a non-limiting example. Specific dosing regimens and / or amounts are also non-limiting. Those of ordinary skill in the art will appreciate that the number of subjects participating in a study can be increased or decreased. Those of ordinary skill in the art will understand how to modify dosage regimens and / or amounts for a particular patient or group of subjects.
[0236] Subjects / patients may be included in the study if they have locally advanced or meta...
PUM
![No PUM](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/noPUMSmall.5c5f49c7.png)
Abstract
Description
Claims
Application Information
![application no application](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/application.06fe782c.png)
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap